Pharma deal values plummet 56% as COVID-19 disrupts resources: report

Over the last few years, Big Pharma executives were more than willing to lay out multiple billions of dollars to acquire companies that could help them pump up their pipelines. Then COVID-19 hit, and suddenly dealmaking became a much different game.